What does Mineralys Therapeutics, Inc. do?
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions…
What is Mineralys Therapeutics, Inc.'s P/E and P/B ratio?
Mineralys Therapeutics, Inc. has a P/E ratio of -5.1 and a P/B ratio of 3.45.
What is Mineralys Therapeutics, Inc.'s debt-to-equity ratio?
Mineralys Therapeutics, Inc. has a debt-to-equity ratio of 0.18.
How much does Mineralys Therapeutics, Inc. owe compared with what it owns?
Mineralys Therapeutics, Inc. owes $0.18 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Mineralys Therapeutics, Inc.'s Positivity rank?
Mineralys Therapeutics, Inc. is ranked #4,137 of 6,774 companies globally and #1,992 of 4,000 in United States on PositoAI, with a Positivity Score of 19,870.
Does Mineralys Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Mineralys Therapeutics, Inc..
Where can I read the latest news about Mineralys Therapeutics, Inc.?
Recent headlines about Mineralys Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Mineralys Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Mineralys Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.